BDX: Company disclosure

ITEM 7.01 REGULATION FD DISCLOSURE. As previously disclosed, on May 6, 2026, Becton, Dickinson and Company ("BD") voluntarily placed ChloraPrep™ and PurPrep™ on ship hold in the U.S. while it conducted additional final release testing. After completion of additional assessments and initiation of final release testing, and to ensure continuity of patient care, we have resumed shipment of ChloraPrep™ in the U.S. To date, all additional final release testing has been acceptable. Additionally, there have been no patient safety signals. The Company had placed the products on ship hold to implement additional release testing, in response to the Warning Letter received from the FDA for the El Paso manufacturing facility (the “El Paso Warning Letter”). For a detailed description of the El Paso Warning Letter and the risks associated with the El Paso Warning Letter, see BD’s Quarterly Report on Form 10-Q for the period ended March 31, 2026. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K, our latest Form 10-Q filing and other our filings with the SEC. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BECTON, DICKINSON AND COMPANY (Registrant) By: /s/ Stephanie M. Kelly Stephanie M. Kelly Chief Securities and Governance Counsel, Corporate Secretary Date: May 29, 2026